+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antidiabetic Drug Market Research Report by Patient, by Disease, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5336317
  • Report
  • September 2021
  • Region: United States
  • 70 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The United States Antidiabetic Drug Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Antidiabetic Drug Market.

Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Antidiabetic Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Patient, the Antidiabetic Drug Market was studied across Adult, Geriatric, and Pediatric.
  • Based on Type, the Antidiabetic Drug Market was studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin is further studied across Intermediate-acting Insulin, Long-acting Analog, Premixed Insulin, Rapid-acting Analog, and Short-acting Analog.
  • Based on Disease, the Antidiabetic Drug Market was studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.
  • Based on State, the Antidiabetic Drug Market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antidiabetic Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Antidiabetic Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Antidiabetic Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Antidiabetic Drug Market?
4. What is the competitive strategic window for opportunities in the United States Antidiabetic Drug Market?
5. What are the technology trends and regulatory frameworks in the United States Antidiabetic Drug Market?
6. What is the market share of the leading vendors in the United States Antidiabetic Drug Market?
7. What modes and strategic moves are considered suitable for entering the United States Antidiabetic Drug Market?
Note: Product cover images may vary from those shown
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Patient Outlook
3.4. Type Outlook
3.5. Disease Outlook
3.6. State Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges

6. Antidiabetic Drug Market, by Patient
6.1. Introduction
6.2. Adult
6.3. Geriatric
6.4. Pediatric

7. Antidiabetic Drug Market, by Type
7.1. Introduction
7.2. Alpha-glucosidase Inhibitors
7.3. Biguanides
7.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
7.5. GLP-1 (Glucagon-like Peptide) Agonists
7.6. Insulin
7.6.1. Intermediate-acting Insulin
7.6.2. Long-acting Analog
7.6.3. Premixed Insulin
7.6.4. Rapid-acting Analog
7.6.5. Short-acting Analog
7.7. Meglitinides
7.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
7.9. Sulphonylureas
7.10. Thiazolidinedione

8. Antidiabetic Drug Market, by Disease
8.1. Introduction
8.2. Diabetes Mellitus Type 1
8.3. Diabetes Mellitus Type 2

9. California Antidiabetic Drug Market
9.1. Introduction

10. Florida Antidiabetic Drug Market
10.1. Introduction

11. Illinois Antidiabetic Drug Market
11.1. Introduction

12. New York Antidiabetic Drug Market
12.1. Introduction

13. Ohio Antidiabetic Drug Market
13.1. Introduction

14. Pennsylvania Antidiabetic Drug Market
14.1. Introduction

15. Texas Antidiabetic Drug Market
15.1. Introduction

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 (USD MILLION)
FIGURE 3. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 (USD MILLION)
FIGURE 4. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 (USD MILLION)
FIGURE 5. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 6. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 7. UNITED STATES ANTIDIABETIC DRUG MARKET: MARKET DYNAMICS
FIGURE 8. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2026 (%)
FIGURE 9. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2026
FIGURE 11. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, 2018-2026 (USD MILLION)
FIGURE 12. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 13. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, 2018-2026 (USD MILLION)
FIGURE 14. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 15. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, 2018-2026 (USD MILLION)
FIGURE 16. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 17. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 18. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2026
FIGURE 20. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2018-2026 (USD MILLION)
FIGURE 21. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 22. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, 2018-2026 (USD MILLION)
FIGURE 23. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 24. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, 2018-2026 (USD MILLION)
FIGURE 25. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 26. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, 2018-2026 (USD MILLION)
FIGURE 27. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 28. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, 2018-2026 (USD MILLION)
FIGURE 29. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 30. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, 2018-2026 (USD MILLION)
FIGURE 31. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 32. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, 2018-2026 (USD MILLION)
FIGURE 33. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 34. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, 2018-2026 (USD MILLION)
FIGURE 35. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 36. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, 2018-2026 (USD MILLION)
FIGURE 37. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 38. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, 2018-2026 (USD MILLION)
FIGURE 39. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 40. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, 2018-2026 (USD MILLION)
FIGURE 41. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 42. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, 2018-2026 (USD MILLION)
FIGURE 43. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 44. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, 2018-2026 (USD MILLION)
FIGURE 45. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 46. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, 2018-2026 (USD MILLION)
FIGURE 47. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 48. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2026 (%)
FIGURE 49. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2026 (USD MILLION)
FIGURE 50. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2026
FIGURE 51. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, 2018-2026 (USD MILLION)
FIGURE 52. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 53. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, 2018-2026 (USD MILLION)
FIGURE 54. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 55. CALIFORNIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 56. FLORIDA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 57. ILLINOIS ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 58. NEW YORK ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 59. OHIO ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 60. PENNSYLVANIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 61. TEXAS ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. UNITED STATES ANTIDIABETIC DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 63. UNITED STATES ANTIDIABETIC DRUG MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 64. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ANTIDIABETIC DRUG MARKET, BY TYPE

List of Tables
TABLE 1. UNITED STATES ANTIDIABETIC DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD MILLION)
TABLE 5. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY STATE, 2018-2026 (USD MILLION)
TABLE 6. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY STATE, 2018-2026 (USD MILLION)
TABLE 7. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY STATE, 2018-2026 (USD MILLION)
TABLE 8. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD MILLION)
TABLE 9. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY STATE, 2018-2026 (USD MILLION)
TABLE 10. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY STATE, 2018-2026 (USD MILLION)
TABLE 11. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY STATE, 2018-2026 (USD MILLION)
TABLE 12. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY STATE, 2018-2026 (USD MILLION)
TABLE 13. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY STATE, 2018-2026 (USD MILLION)
TABLE 14. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY STATE, 2018-2026 (USD MILLION)
TABLE 15. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY STATE, 2018-2026 (USD MILLION)
TABLE 16. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY STATE, 2018-2026 (USD MILLION)
TABLE 17. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY STATE, 2018-2026 (USD MILLION)
TABLE 18. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY STATE, 2018-2026 (USD MILLION)
TABLE 19. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY STATE, 2018-2026 (USD MILLION)
TABLE 20. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY STATE, 2018-2026 (USD MILLION)
TABLE 21. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY STATE, 2018-2026 (USD MILLION)
TABLE 22. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY STATE, 2018-2026 (USD MILLION)
TABLE 23. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD MILLION)
TABLE 24. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY STATE, 2018-2026 (USD MILLION)
TABLE 25. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY STATE, 2018-2026 (USD MILLION)
TABLE 26. CALIFORNIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. FLORIDA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. ILLINOIS ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. NEW YORK ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. OHIO ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. PENNSYLVANIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. TEXAS ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. UNITED STATES ANTIDIABETIC DRUG MARKET: SCORES
TABLE 34. UNITED STATES ANTIDIABETIC DRUG MARKET: BUSINESS STRATEGY
TABLE 35. UNITED STATES ANTIDIABETIC DRUG MARKET: PRODUCT SATISFACTION
TABLE 36. UNITED STATES ANTIDIABETIC DRUG MARKET: RANKING
TABLE 37. UNITED STATES ANTIDIABETIC DRUG MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 38. UNITED STATES ANTIDIABETIC DRUG MARKET: MERGER & ACQUISITION
TABLE 39. UNITED STATES ANTIDIABETIC DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 40. UNITED STATES ANTIDIABETIC DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 41. UNITED STATES ANTIDIABETIC DRUG MARKET: INVESTMENT & FUNDING
TABLE 42. UNITED STATES ANTIDIABETIC DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 43. UNITED STATES ANTIDIABETIC DRUG MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll